Clinical benefits of switching type 2 diabetes patients from human insulins to insulin analogs
https://doi.org/10.14341/probl201359677-79
Abstract
Achievement and long-term maintenance of optimal glucose control is still a big problem in many patients with type 2 diabetes. Diabetes related complications and cardiovascular diseases also can do more difficult the choice of glucose lowering therapy. Insulin therapy is the most effective method of treatment in such patients. However treatment with human insulin is often associated with hypoglycemia and weight gain, which are additional barriers to achieve glycemic control. Presented clinical cases show that switching from human insulin for insulin analogues detemir (Levemir) and aspart (NovoRapid) provide a significant improvement in glycemic control without increasing of risk of hypoglycemia and weight gain.
References
1. Кудинов В.И., Ничитенко М.С. Сравнительная оценка эффективности различных схем инсулинотерапии у больных сахарным диабетом 2-го типа и ишемической болезнью сердца. Сахарный диабет 2012; 2: 23-27.
2. Fuchtenbusch M., Hummel M. Intensive blood sugar treatment in type 2 diabetics: no evidence for increased mortality in the ADVANCE study compared with ACCORD study. MMW Fortschr Med 2008; 150: 17: 42-44.
3. Anderson J.H. Jr, Brunelle R.L., Koivisto V.A., Pfützner A., Trautmann M.E., Vignati L., DiMarchi R. Reduction of postprandial hyper-glycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Diabetes 1997; 46: 265-270.
4. Hirsch I. Insulin analogues. N Engl J Med 2005; 352: 174-183.
Review
For citations:
Kudinov V.I., Nichitenko M.S., Ibragimova V.A. Clinical benefits of switching type 2 diabetes patients from human insulins to insulin analogs. Problems of Endocrinology. 2013;59(6):77-79. (In Russ.) https://doi.org/10.14341/probl201359677-79
Views:
472
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
.jpg){kind=logo}
